Anth
http://www.chiro.org/nutrition/ABSTRACTS/Natural_Agents_in_-
Prevention_PART_1.shtml Megadose Nutrients in Bladder Cancer
A double-blind, placebo-controlled trial using a combination
of vitamins and minerals was employed to determine if the
recurrence of superficial bladder cancer could be prevented
post-resection.7 After tumor resection 65 patients were
randomized to receive either a multi-vitamin/zinc supplement
with RDA concentrations of all components, or the RDA multi-
vitamin/zinc supplement plus 40,000 IU vitamin A acetate,
100 mg vitamin B6, 2,000 mg vitamin C, 400 IU vitamin E, and
90 mg zinc per day. Patients were also randomized to receive
intravesicular administration of BCG with or without
percutaneous BCG administration (BCG is an immune-
stimulating bacillus). During five years of supplementation,
tumor recurrence was seen in 80 percent of the RDA vitamin-
supplemented group, but in only 40 percent of those
receiving the mega-dose vitamin therapy (p = 0.0011).
Although the patient survival rate was nearly identical
between treatment groups, the interval-to-death in the RDA
group patients was 18.6 months but 33 months in the mega-
dose vitamin group (p = NS). Addition of percutaneous BCG to
the therapeutic regimen did not affect the results.
Several important conclusions can be drawn from these data.
One is that the paradigm of supplementation of antioxidants
and other nutrients as a group is an effective means of
preventing bladder cancer recurrence. The lack of reduction
in mortality may reflect an inability to help those patients
who had the most genetic damage (and thus the most
aggressive tumors) at the outset of the study. Instead, what
this treatment was likely doing was protecting against
further genetic mutations of the tissue around the
resections.
Anth
Prevention_PART_1.shtml Megadose Nutrients in Bladder Cancer
A double-blind, placebo-controlled trial using a combination
of vitamins and minerals was employed to determine if the
recurrence of superficial bladder cancer could be prevented
post-resection.7 After tumor resection 65 patients were
randomized to receive either a multi-vitamin/zinc supplement
with RDA concentrations of all components, or the RDA multi-
vitamin/zinc supplement plus 40,000 IU vitamin A acetate,
100 mg vitamin B6, 2,000 mg vitamin C, 400 IU vitamin E, and
90 mg zinc per day. Patients were also randomized to receive
intravesicular administration of BCG with or without
percutaneous BCG administration (BCG is an immune-
stimulating bacillus). During five years of supplementation,
tumor recurrence was seen in 80 percent of the RDA vitamin-
supplemented group, but in only 40 percent of those
receiving the mega-dose vitamin therapy (p = 0.0011).
Although the patient survival rate was nearly identical
between treatment groups, the interval-to-death in the RDA
group patients was 18.6 months but 33 months in the mega-
dose vitamin group (p = NS). Addition of percutaneous BCG to
the therapeutic regimen did not affect the results.
Several important conclusions can be drawn from these data.
One is that the paradigm of supplementation of antioxidants
and other nutrients as a group is an effective means of
preventing bladder cancer recurrence. The lack of reduction
in mortality may reflect an inability to help those patients
who had the most genetic damage (and thus the most
aggressive tumors) at the outset of the study. Instead, what
this treatment was likely doing was protecting against
further genetic mutations of the tissue around the
resections.
Anth
